Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power by Khan, I et al.
Smaller sample sizes for phase II trials based on exact tests with
actual error rates by trading-off their nominal levels of significance
and power
I Khan*,1, S-J Sarker2 and A Hackshaw1
1Cancer Research UK and UCL Cancer Trials Centre, University College London, 90 Tottenham Court Road (fifth floor), London, UK; 2Centre for
Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK
BACKGROUND: Sample sizes for single-stage phase II clinical trials in the literature are often based on exact (binomial) tests with levels
of significance (alpha (a)o5% and power480%). This is because there is not always a sample size where a and power are exactly
equal to 5% and 80%, respectively. Consequently, the opportunity to trade-off small amounts of a and power for savings in sample
sizes may be lost.
METHODS: Sample-size tables are presented for single-stage phase II trials based on exact tests with actual levels of significance and
power. Trade-off in small amounts of a and power allows the researcher to select from several possible designs with potentially
smaller sample sizes compared with existing approaches. We provide SAS macro coding and an R function, which for a given
treatment difference, allow researchers to examine all possible sample sizes for specified differences are provided.
RESULTS: In a single-arm study with P0 (standard treatment)¼ 10% and P1 (new treatment)¼ 20%, and specified a¼ 5% and
power¼ 80%, the A’Hern approach yields n¼ 78 (exact a¼ 4.53%, power¼ 80.81%). However, by relaxing a to 5.67% and power
to 77.7%, a sample size of 65 can be used (a saving of 13 patients).
INTERPRETATION: The approach we describe is especially useful for trials in rare disorders, or for proof-of-concept studies, where it is
important to minimise the trial duration and financial costs, particularly in single-arm cancer trials commonly associated with expensive
treatment options.
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Phase II clinical trials are common in medical research,
particularly in oncology. They are often based on a relatively
small or moderate number of patients (typically 40–70), and allow
a preliminary assessment of a new intervention before embarking
on a larger and expensive randomised controlled trial (i.e., phase
III). Many new drugs are not investigated beyond phase II, because
of evidence that they are ineffective. The Fleming single-stage
procedure (Fleming, 1982 (for the situation where K¼ 1); Machin
et al, 1997; A’Hern, 2001) has been a widely used approach in
early-phase drug development. It involves having a single
treatment group, and all patients are given the test intervention
(often called a single-arm, single-stage design). The observed data
are considered in relation to historical data expected to be
associated with the control/standard treatment in order to design a
subsequent phase III study.
Multistage designs involve conducting one or more interim
analyses to decide whether all patients planned for a trial should be
recruited. A decision to proceed to phase III is determined by
using patient data from all stages of accrual. One important
advantage of a multistage design relates to fewer patients on
ineffective experimental treatments, with the opportunity to stop a
trial earlier for futility (Schlesselman et al, 2006).
Recently, randomised controlled phase II trials are becoming
more popular, particularly for common cancers, in which patients
are randomly allocated to receive either the test intervention or the
control (e.g., the standard treatment or placebo), or they are
randomised to several experimental treatments. An important
advantage of this approach is that the control group data are
collected prospectively, that is, at the same time as those given the
new intervention, and this usually yields more reliable data from
which to design a subsequent phase III trial. A review and discussion
of phase II designs is given in Rubinstein et al (2005), Ratain and
Sargent (2009), Daniel et al (2009) and Sargent and Taylor (2009).
The basic idea of a phase II design is that a new therapy is worth
considering further if it demonstrates a level of treatment
response, P1 (e.g., tumour response or lower disease progression),
which is greater than the response rate for the current or standard
treatment, P0. Values of P1 and P0 are estimates of p1 and p0,
respectively, the true probability of response, and used for sample-
size calculations, along with desired statistical power and level of
statistical significance.
The sample-size method in a single-stage Fleming design uses a
normal approximation to the binomial distribution, and this
helped facilitate the calculations for multiple stage testing.
However, the sample sizes using this approximation result in
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differences in sample sizes compared with exact methods,
particularly for relatively small studies. This is discussed in
A’Hern (2001), who also provided sample-size tables using exact
methods, which are larger than those obtained using the Fleming
(1982) design. The difference is noticeable for studies of say o50
patients. The Fleming design can also produce anomalous results
in that the confidence interval for the observed proportion could
include P0, even though the P-value is o0.05 (A’Hern, 2001). It is
therefore better to use exact tests. Although the idea of using alpha
(a) levels greater than threshold values, such as 5 or 10%, was
mentioned briefly, the impact on sample size was not discussed
(A’Hern, 2001). A’Hern (2001) provides sample sizes based on
approximate a levels and power.
Sample-size software (Hintze, 2001; Machin et al, 2009) and
tables (A’Hern, 2001; Machin et al, 2009) are available for the
Fleming design and A’Hern exact sample sizes. However, they are
based on conventional significance levels, such as 5 or 10%, and
power, such as 80 or 90%. This means that the sample sizes
produced are based on ensuring an ap5% and powerX80%; but
researchers might think that a¼ 5% and power¼ 80%. In some
situations, smaller sample sizes for a¼ 5.1% and power¼ 79.9%
might be possible and therefore ignored. It can be difficult to
choose from a wider set of possible sample sizes if software or
tables only offer a solution where a is p5% and power is X80%.
Even with some specialist software, such as PASS (Hintze, 2001), it
would require inputting a large number of non-standard a and
power values either one at a time or in some other way. If we
accept an a level that is ‘around’ 10% and power ‘around’ 80%,
then more than one possible sample size can arise (shown later).
The consequence of this is that software programs and the tables
presented by A’Hern (2001) give sample sizes based on
approximate a levels and power.
This paper considers the implications of such approximations in
clinical trials in practice and presents sample size for exact a levels
based on the exact test. We can then use this approach to examine
several sample sizes for the same treatment effect and choose one
that is the smallest. This would be especially useful for studies of
novel agents (where little is known about the treatment) or for rare
disorders, where it is appropriate to minimise the sample size.
MATERIALS AND METHODS
With a single-stage design, the standard response rate is assumed
to be P0 (under the null hypothesis); and the new therapy is
considered worthy of further research if we can reject the null
hypothesis in favour of the alternative hypothesis, where the
response rate is P1. For example, a current therapy may be
associated with a 50% tumour response rate for a given cancer, and
a new agent or intervention is considered potentially useful if it can
increase the rate to at least 65%. The consequent decision rule
provides the sample size (n) and minimum number of responders
(i.e., Xr) that are required to warrant further investigation of the
new therapy, such that statistical significance is achieved. If the
number of responders is or, then this number is the maximum
number of responders for which statistical significance is not
achieved.
The above can be formally stated as:
H0 : P0 p50% vs H1 : P1 X65%
UnderH0 : Prðr out of n to the treatment ðP0¼ 0:5Þ is Bin ðn; P0; rÞÞ
ð1Þ
UnderH1 : Pr ðr out of n to the treatment ðP1¼ 0:65Þ is Bin ðn;P1; rÞÞ
ð2Þ
The term Bin(n, P1, r) states that responses are from a Binomial
distribution with parameters P1, the probability of a response, r,
the number of responders to the new treatment and n, the sample
size.
The approach to computing (1) and (2) is shown below in (3)
and (4) respectively, as described by Chow et al (2003).
Xn
k¼ r
n !
k ! ðn kÞ ! P
k
0ð1 P0Þn kpa ð3Þ
Xn
k¼ r
n !
k ! ðn kÞ ! P
k
1ð1 P1Þn kX1 b ð4Þ
From Equation 3, we generate the observed significance level (a)
and this value is compared against the pre-specified significance
level (i.e., 5 or 10%). We also require values from Equation 4 to be
X80%. Sample sizes are then chosen when the observed a levels
are o5% (or 10%) and when the power is X80%.
RESULTS
Table 1 uses a range of differences between P0 and P1 to show how
sample size can vary if we accept a significance level or power that
are not exactly equal to conventionally accepted levels. Interest is
in whether there is a value of a that is not much larger than the
usual specified level of 5 or 10%, or a value of power which is not
mucho80%, but where there is a reduction in sample size. Table 1
shows the exact a and power values compared with the tables from
A’Hern (2001). In Table 1, we show only the first five solutions
ordered by sample size where available, for sample sizes 420, for
absolute differences between P0 and P1 ranging 10–30%. Smaller
differences (i.e., o10%) are not considered clinically important in
most trials. The value of a has been increased to a limit of 8%
where the planned (target) a was 5% (target þ 3%). For a target a
of 10%, the limit is 13%. The sample sizes are presented with
power always X77%. The exact a and power values are computed
only when the sample size requirement is 420, because sample
sizeso20 pose less of a problem in recruitment terms. A SAS macro
is also provided (Appendix I), which can be used to derive sample
sizes, power and a values for all possibilities of P0 and P1, but other
software such as R can also be used. The SAS program requires the
user to input ranges of P0 and P1 and also uses cut-offs of 0.08 for
a (i.e., target a þ 3%) and 0.77 for power, which we consider as
constituting a ‘small trade-off’. We illustrate the use of Table 1 using
some examples. A Corresponding R function is also available in the
Clinfun package written by Seshan (2012), see Appendix II.
Example 1: single-arm phase II study
Aogi et al (2011) report a single-arm trial designed to detect a
small difference of 10% in Japanese breast cancer patients. We use
the same parameters in the context of a single-arm trial with
P0¼ 10% and P1¼ 20%, a¼ 5% (one sided) and power¼ 80% to
demonstrate the impact of trading-off type I and II error rates.
There is no exact solution for this design. Fleming approximation
using the formulae as presented in Machin et al (2009) gives the
solution as sample size n¼ 69 and number of response r¼ 12,
which (based on exact method) is actually coming from exact
a¼ 4% and exact power¼ 75.04%. The A’Hern method in the
sample-size software (Machin et al, 2009) gives the solution to the
same problem as 13 out of 78, which actually come from a¼ 4.53%
and power¼ 80.81% (Table 1, first row entries in bold).
Further examination of Table 1 shows alternative sample sizes
obtained by relaxing a and power (savings in sample sizes are shown
by comparing the bold figures in the first row with the sample sizes
immediately below), and also for differences 410%. By accepting
a¼ 5.67% and power¼ 77.7%, both of which are reasonably close to
the specified levels of 5 and 80%, and the solution is 11 out of 65,
which is smaller than Fleming (12 out of 69) but the power is
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Table 1 Sample sizes based on exact binomial test
Target a¼ 5% (þ 3%) Target a¼ 10% (þ 3%)
P0 P1 Exact a (%) Exact Power r\n Exact a (%) Exact Power r\n
0.10 0.20 4.53 80.81 13\78 7.99 80.41 10\61
7.31 78.68 10\60 10.21 77.08 8\48
7.99 80.41 10\61 11.19 79.09 8\49
5.67 77.71 11\65 12.21 80.96 8\50
6.21 79.42 11\66 10.30 81.49 9\56
6.79 81.04 11\67 11.20 83.11 9\57
0.10 0.25 4.19 81.80 8\40 8.34 82.35 6\31
7.32 79.74 6\30 11.18 81.56 5\26
5.52 80.80 7\35 12.66 84.17 5\27
6.28 83.16 7\36
7.11 85.28 7\37
8.00 87.18 7\38
0.10 0.30 3.33 80.65 6\25 9.81 83.54 4\18
5.22 80.16 5\21 no20
6.21 83.55 5\22
7.31 86.44 5\23
0.10 0.35 2.81 81.11 5\18 5.55 82.73 4\15
no20 no20
0.15 0.25 4.33 80.42 22\101 8.88 80.54 16\75
6.90 78.11 17\78 12.50 77.65 12\56
7.61 79.90 17\79 11.74 78.94 13\61
5.91 77.52 18\82 12.92 80.90 13\62
6.53 79.30 18\83 10.00 78.18 14\65
7.19 80.98 18\84 11.03 80.13 14\66
0.15 0.30 4.77 81.85 12\48 9.23 82.37 9\37
5.79 77.59 10\39 11.52 77.98 7\28
6.72 80.41 10\40 11.07 81.78 8\33
7.74 82.95 10\41 12.67 84.42 8\34
5.66 81.15 11\44
6.51 83.53 11\45
0.15 0.35 4.85 81.79 8\28 9.99 83.71 6\22
5.72 78.94 7\24 12.06 81.14 5\18
6.95 82.66 7\25 11.89 86.91 6\23
0.15 0.40 3.68 84.15 7\21 7.90 83.34 5\16
6.17 78.27 5\15 no20
7.91 83.34 5\16
5.37 83.71 6\19
6.73 87.44 6\20
0.15 0.45 4.67 83.28 5\14 6.94 80.88 4\11
no20 no20
0.20 0.30 4.86 80.72 31\116 9.84 81.71 23\88
7.99 77.93 23\86 12.03 77.63 18\68
7.70 78.80 24\90 11.56 78.54 19\72
6.67 77.72 25\93 12.83 80.62 19\73
7.42 79.62 25\94 11.10 79.40 20\76
6.44 78.58 26\97 12.30 81.38 20\77
0.20 0.35 4.32 80.64 17\56 8.57 81.96 13\44
7.33 79.08 13\43 12.87 77.53 9\30
6.15 78.75 14\46 10.68 77.01 10\33
7.21 81.57 14\47 12.54 80.45 10\34
5.17 78.45 15\49 10.46 79.92 11\37
6.07 81.22 15\50 12.19 82.91 11\38
0.20 0.40 3.43 80.48 12\35 8.91 80.80 8\24
5.92 77.45 9\26 10.85 79.98 7\21
7.37 81.61 9\27
6.11 82.37 10\30
7.46 85.66 10\31
5.08 83.10 11\33
0.20 0.45 4.30 80.29 8\21 8.16 80.24 6\16
5.13 77.42 7\18 no20
6.76 82.73 7\19
0.20 0.50 3.76 83.80 7\17 7.25 80.61 5\12
no20 no20
0.25 0.35 4.93 80.39 41\129 9.93 80.91 30\96
7.80 78.79 32\101 12.65 77.11 23\73
7.31 78.75 33\104 11.81 77.03 24\76
6.85 78.72 34\107 12.39 79.28 25\80
7.68 80.64 34\108 11.58 79.18 26\83
6.43 78.69 35\110 12.94 81.32 26\84
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Table 1 (Continued )
Target a¼ 5% (þ 3%) Target a¼ 10% (þ 3%)
P0 P1 Exact a (%) Exact Power r\n Exact a (%) Exact Power r\n
0.25 0.40 4.28 80.31 22\62 8.96 80.78 16\46
7.53 77.51 16\45 11.09 77.83 13\37
7.04 78.56 17\48 10.32 78.88 14\40
6.59 79.54 18\51 12.22 82.19 14\41
7.81 82.45 18\52 11.35 82.97 15\44
5.17 77.41 19\53
0.25 0.45 4.61 81.67 14\36 9.08 80.64 10\26
6.79 78.65 11\28 12.99 80.29 8\21
6.44 81.13 12\31 12.13 82.70 9\24
6.10 83.26 13\34
7.56 86.56 13\35
5.77
0.25 0.50 4.00 83.65 11\26 7.74 82.03 8\19
7.96 77.28 7\16 no20
7.75 82.04 8\19
5.61 80.83 9\21
7.46 85.69 9\22
5.47 84.63 10\24
0.25 0.55 4.02 81.65 8\17 8.02 82.12 6\13
no20 no20
0.30 0.40 4.73 80.67 53\144 9.00 80.13 39\107
7.98 77.06 38\103 11.99 77.04 30\82
7.96 77.94 39\106 11.93 77.98 31\85
7.94 78.79 40\109 11.88 78.88 32\88
6.99 77.41 41\111 10.43 77.33 33\90
7.92 79.59 41\112 11.82 79.73 33\91
0.30 0.45 4.66 81.46 27\67 8.48 80.26 20\50
7.17 78.99 21\52 11.51 78.58 16\40
6.05 77.74 22\54 11.69 80.84 17\43
7.31 81.04 22\55 11.83 82.83 18\46
6.20 79.87 23\57 10.02 81.54 19\48
7.44 82.88 23\58 11.94 84.60 19\49
0.30 0.50 4.99 83.16 17\39 8.44 81.92 13\30
7.98 77.90 12\27 12.01 79.76 10\23
6.52 77.09 13\29 12.53 83.65 11\26
6.94 81.15 14\32 10.28 82.75 12\28
5.71 80.42 15\34 12.94 86.75 12\29
7.31 84.47 15\35
0.30 0.55 4.42 81.73 12\25 8.39 81.58 9\19
6.76 81.59 10\21 no20
5.46 81.64 11\23
7.42 86.59 11\24
0.30 0.60 4.02 80.10 9\17 9.32 84.98 7\14
no20 no20
0.35 0.45 4.86 80.00 62\148 9.39 80.17 46\111
7.54 77.01 47\112 12.87 78.37 36\87
7.94 78.68 48\115 11.80 77.47 37\89
7.30 77.93 49\117 12.40 79.27 38\92
6.70 77.18 50\119 11.38 78.41 39\94
7.68 79.52 50\120 12.99 80.93 39\95
0.35 0.50 4.60 80.19 31\68 9.77 80.41 22\49
7.87 79.49 24\53 12.39 78.52 18\40
7.07 79.06 25\55 11.07 77.96 19\42
6.35 78.65 26\57 12.15 81.44 20\45
7.78 82.09 26\58 10.89 80.92 21\47
5.70 78.25 27\59
0.35 0.55 4.80 83.09 20\41 9.77 81.99 14\29
5.78 77.28 16\32 12.54 81.73 12\25
7.68 82.32 16\33 11.06 81.85 13\27
5.14 77.64 17\34
6.82 82.51 17\35
6.06 82.69 18\37
0.35 0.60 3.77 80.06 14\26 9.99 80.10 9\17
7.72 82.56 11\21 no20
6.82 83.64 12\23
6.04 84.62 13\25
5.36 85.53 14\27
7.36 89.75 14\28
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Table 1 (Continued )
Target a¼ 5% (þ 3%) Target a¼ 10% (þ 3%)
P0 P1 Exact a (%) Exact Power r\n Exact a (%) Exact Power r\n
0.35 0.65 3.46 81.45 11\19 7.53 81.64 8\14
7.53 81.64 8\14
6.71 84.06 9\16 no20
5.97 86.09 10\18
5.32 87.82 11\20
7.72 92.28 11\21
0.40 0.50 4.79 80.92 74\158 9.87 80.24 52\112
7.75 77.21 54\115 12.48 77.21 41\88
7.39 77.02 55\117 12.51 79.40 44\95
7.81 79.24 57\122 11.92 79.16 45\97
7.46 78.05 58\124 11.36 78.92 46\99
7.12 78.86 59\126 10.82 78.69 47\101
0.40 0.55 4.37 80.17 36\71 9.78 80.33 25\50
6.61 77.24 28\55 12.98 78.70 20\40
6.27 77.64 29\57 12.25 79.04 21\42
7.87 81.54 29\58 11.57 79.37 22\44
5.96 78.03 30\59 10.93 79.70 23\46
7.46 81.83 30\60 10.34 80.02 24\48
0.40 0.60 3.75 80.31 23\42 9.70 82.46 16\30
6.77 78.06 17\31 12.07 77.20 12\22
6.45 79.41 18\33 11.43 78.70 13\24
6.15 80.65 19\35 10.82 80.07 14\26
5.86 81.80 20\37 10.25 81.32 15\28
7.84 86.24 20\38 12.84 87.16 16\31
0.40 0.65 4.99 85.72 16\28 8.84 81.45 11\19
5.51 79.16 13\22 no20
5.35 81.67 14\24
7.78 87.46 14\25
5.18 83.84 15\26
7.43 88.94 15\27
0.40 0.70 3.50 81.80 12\19 9.76 83.46 8\13
no20 no20
0.45 0.55 4.95 80.03 80\154 9.90 82.20 62\121
7.10 77.07 63\121 12.13 77.32 47\91
7.01 77.44 64\123 11.96 77.70 48\93
6.93 77.79 65\125 11.80 78.07 49\95
6.85 78.14 66\127 11.64 78.43 50\97
6.77 78.48 67\129 11.49 78.78 51\99
0.45 0.60 4.66 80.39 39\70 9.98 82.29 29\53
7.79 77.87 29\52 10.17 77.77 25\45
7.78 79.06 30\54 10.14 79.02 26\47
7.76 80.18 31\56 12.91 83.47 26\48
7.74 81.23 32\58 10.09 80.18 27\49
6.01 78.05 33\59 12.79 84.38 27\50
0.45 0.65 4.15 81.82 25\42 9.92 82.07 17\29
7.14 78.02 18\30 9.59 77.11 15\25
7.29 80.43 19\32 9.78 79.76 16\27
7.42 82.57 20\34
5.36 78.91 21\35
7.52 84.46 21\36
0.45 0.70 4.39 81.05 16\25 8.71 81.80 12\19
5.80 77.23 13\20 no20
6.17 81.35 14\22
6.48 84.72 15\24
6.74 87.47 16\26
0.45 0.75 4.86 81.03 11\16 7.69 85.16 10\15
no20 no20
0.50 0.60 4.72 80.56 90\158 9.57 80.45 65\115
7.98 77.28 65\114 12.31 77.52 51\90
7.27 77.73 69\121 12.57 78.52 52\92
7.44 78.63 70\123 12.82 79.48 53\94
7.61 79.49 71\125 11.14 77.92 55\97
6.48 77.28 72\126 11.38 78.88 56\99
0.50 0.65 4.55 80.20 42\69 8.44 80.32 32\53
6.68 77.27 33\54 12.79 77.49 23\38
7.04 79.30 34\56 11.10 78.50 26\43
7.40 81.16 35\58 11.63 80.60 27\45
5.87 78.32 36\59 12.15 82.51 28\47
7.75 82.86 36\60 12.64 84.22 29\49
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also higher. Compared with A’Hern, the sample size 78, there is a
saving of 13. This means that the chance of declaring the new agent
as being beneficial when in reality it is not has only increased
by 1.14 (from 4.53% to 5.67%) percentage points, and power has
decreased by 3.10 percentage points. On the other hand, the increase
of a is only 0.67% when compared with the conventional 5%.
This could be considered worthwhile in relation to the potential
saving in financial costs and accrual time, as well as exposing fewer
patients to a novel agent that may have serious side effects.
Example 2: randomised controlled phase II study (1 : 1
allocation)
We take P0¼ 30% and P1¼ 40%; and specify a¼ 10% and
power¼ 80%. Again, there is no exact solution for this when
a¼ 10% and power¼ 80%. Sample-size software and tables from
A’Hern (2001) give the solution as n¼ 107 and r¼ 39, which has an
exact a¼ 9.00% and power¼ 80.13%. However, by accepting
a¼ 10.43% and power¼ 77.33% (Table 1), both of which are
reasonably close to the specified levels of 10 and 80%, the sample
size could be 90 patients in one treatment group (instead of 107).
Because there are an equal number of patients in the other
treatment group (which could be another new treatment or a
control group), there would be a total saving of 34 patients. The
increase in a has therefore been 1.43 percentage points (and only
0.43 percentage points from the usual a of 10%); and power has
decreased by only 2.8 percentage points. If the same trial had a 2 : 1
allocation instead of a 1 : 1 (in favour of the new intervention
group), the saving would be 25 patients (17 in the experimental
plus roughly half the number in the control). It should be noted
that although this approach to randomised studies was common, a
more efficient approach is to have a design that involves a direct
comparison of the two treatment groups (Rubinstein et al, 2005;
Jung, 2008).
A practical example
We extend the trade-off approach to an example of a phase II
randomised trial in lung cancer patients using a two-stage design,
which was stopped for lack of efficacy after stage I. A Simon’s two-
stage minimax design with P0¼ 50% and P1¼ 65%, a¼ 10% and
power¼ 90% using the software by Machin et al (2009) gives the
required sample size at stage 1 of 20 out of 40, and total sample
size was 42 out of 72 in each intervention arm. Therefore, total
sample size was 144 due to randomisation. Our exact calculation
reveals that the actual a was 9.7% and power was 90.4% in the
sample-size calculation. The trial had major recruitment problems
and it could have been designed with a¼ 10.4% and
power¼ 88.8% to give a stage 1 sample size of 13 out of 27 and
stage II sample size of 38 out of 65, saving 26 patients at stage I and
Table 1 (Continued )
Target a¼ 5% (þ 3%) Target a¼ 10% (þ 3%)
P0 P1 Exact a (%) Exact Power r\n Exact a (%) Exact Power r\n
0.50 0.70 4.94 80.70 24\37 9.24 80.86 18\28
6.80 77.08 19\29 10.50 77.09 15\23
7.48 80.76 20\31 11.48 81.06 16\25
5.51 77.17 21\32 12.39 84.34 17\27
6.07 80.71 22\34
6.62 83.73 23\36
0.50 0.75 4.65 80.36 16\23 8.35 82.51 13\19
5.77 78.58 14\20 no20
6.69 83.85 15\22
0.50 0.80 4.81 86.70 13\18 8.97 87.01 10\14
no20 no20
0.55 0.65 4.97 80.45 93\150 9.44 80.35 69\112
7.47 77.77 72\116 12.95 78.02 53\86
7.92 79.21 73\118 11.81 77.31 55\89
6.83 77.15 74\119 12.50 78.98 56\91
7.25 78.65 75\121 11.40 78.30 58\94
7.68 80.06 76\123 12.07 79.88 59\96
0.55 0.70 4.52 82.01 46\70 9.48 81.00 32\49
7.65 78.22 33\50 11.96 77.45 25\38
6.87 78.44 35\53 10.67 77.62 27\41
7.64 81.25 36\55 11.84 80.81 28\43
6.17 78.66 37\56 10.59 80.90 30\46
6.86 81.39 38\58 11.65 83.59 31\48
0.55 0.75 4.26 80.59 26\37 9.12 83.36 20\29
7.74 78.59 19\27 12.99 78.58 14\20
6.94 80.34 21\30 11.52 80.37 16\23
5.22 77.10 22\31 10.24 81.95 18\26
6.23 81.90 23\33 11.87 86.15 19\28
7.29 85.79 24\35
0.55 0.80 3.64 81.10 18\24 7.77 83.69 14\19
7.77 83.69 14\19 no20
5.53 80.42 15\20
7.05 86.70 16\22
5.10 84.02 17\23
0.55 0.85 4.24 82.26 12\15 9.95 82.01 8\10
no20
The value of r denotes the number of responders required. Comparison with the numbers in bold shows the potential saving in sample sizes The first entry of each P0 and P1 row
(i.e., in bold) refers to the sample size from A’Hern (2001), which is also produced from software.
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14 patients in total. It is worth noting that both the original design
(n¼ 144) and the alternative design (n¼ 130) have probabilities of
early termination under the null hypothesis of o50%.
DISCUSSION
There are an increasing number of early phase II trials being
conducted, given the availability of many new therapies, which are
used on their own or in combination with the standard treatments.
Furthermore, there is an emerging preference for randomised
controlled phase II studies, which increases the total trial size (Lee
and Feng, 2005; Cannistra, 2009). Phase II trials need to be
conducted as quickly as possible with the minimum of resources,
in order to reject apparently ineffective interventions early on in
drug development and move on to other treatments, or to further
investigate those that look promising. Traditionally, phase II trials
are designed on the basis of the active (new) treatment arm only,
in that the sample size is based on the expected treatment effect in
that arm. If there is a control arm, the number of patients may be
taken to be the same as or half of that in the active arm, depending
on 1 : 1 or 2 : 1 allocation, respectively.
The financial costs of conducting a clinical trial have increased,
particularly in light of the current regulations and governance, so
that it can take many months (46) to set up a study (Hackshaw
et al, 2008). Having a small study, where acceptable, can therefore
have clear benefits in terms of shorter trial duration, which is
associated with lower costs. Another benefit is that fewer patients
are exposed to a novel agent that has serious side effects but is
eventually shown to be ineffective. Minimising sample size is
particularly important for rare disorders where recruiting even
10–15 patients could take several months.
When designing studies, most researchers use established values
for a of 5 or 10% and power of 80% (occasionally 90%). In our
paper, we show that by allowing slightly higher a and lower power
for these exact tests, there could be a material reduction in sample
size, particularly for studies with sayo50 patients. We believe that
such an approach is useful for two reasons. First, phase II trials are
usually only meant to provide preliminary evidence of efficacy,
therefore relaxing the design parameters should not be of great
concern. Second, the conventional values of a¼ 5% and power
80% were somewhat arbitrary when originally stipulated; they were
not selected on the basis of scientific principles (a¼ 5% was
judged sufficiently low and power¼ 80% as sufficiently high).
However, these values were primarily meant for large confirmatory
studies, but researchers and reviewers involved in grant applica-
tions have not often relaxed them for exploratory studies, such as
phase II trials. Recently, it has become more common to have
values of a of X10% in cancer trials (Rubinstein et al, 2005).
Therefore, accepting a of 7% instead of 5%, or power of 77%
instead of 80%, could be considered a worthwhile trade-off for
having a smaller study, particularly when the largest savings are
made with randomised controlled phase II trials.
Our approach to sizing studies is not just limited to single-stage
designs, but can also be extended to two-stage (Simon, 1989) and
other n-stage designs where exact methods are used. In some two-
stage design, trade-offs in the expected sample size are considered
for smaller overall sample sizes (Jung et al, 2001). By compromis-
ing a and power in addition to the expected sample size, it is
possible that savings in sample size are even greater. However,
additional complexities such as the probability of early termina-
tion might also be important when considering any trade-off.
The implications of trading-off type I and II errors is that the
risk of a false-positive or -negative may be slightly above or below
the conventional 5% and 80%, respectively. The specific type of
trade-off is likely to be based on feasibility and may vary from trial
to trial. However, in phase II trials, which are often about finding
preliminary evidence of effect, a trade-off in either direction may
be possible. It is important to point out that such a trade-off does
not influence the size of the treatment benefit.
A limitation of our suggested approach is that the final result
ideally needs to be considered in relation to the a level used in the
sample-size calculation, which is not a round number such as 5%
or 10%. However, even when sample sizes come from A’Hern
(2001) or software, the interpretation of the primary result is based
on a¼ 5%, even though the actual value might be 4.5%. Moreover,
reported P-values such as ‘0.052’ or ‘0.057’ (in the context of phase
III trials) are not readily dismissed for lack of effect (Hackshaw
and Kirkwood, 2011), and therefore powering a trial with non-
standard a and power may also be considered a reasonable
approach for phase II study designs. Nevertheless, the decision on
whether or not to investigate a new treatment further should not be
based on a single numerical cut-off for a, but perhaps on
consideration of several pieces of information, including other
clinically important efficacy end points, safety and accrual rates. It
is often the case that a smaller treatment effect is observed, and
precision would be lost by having a study that is too small, making
it difficult to determine whether to investigate the new therapy
further or not. We therefore do not recommend that sample sizes
be reduced to o20 patients per treatment group.
In conclusion, it is worthwhile examining a fuller range of
sample sizes when using exact methods for single-stage phase II
trials, so that the smallest acceptable sample size could be chosen
after allowing a slightly higher a level (error rate) than the
conventional 5 or 10%, and lower power than the nominal 80%.
This can lead to benefits such as shorter study duration and lower
financial costs, which are key considerations when investigating
treatments for uncommon disorders or new agents in proof-of-
concept studies, and this could make a project proposal being
considered for funding more attractive when peer-reviewed. When
the decision rule is based on the experimental arm alone, but the
study is a randomised parallel group design, the differences in
sample size between the approaches described here and those
presented by A’Hern can be up to 25% lower after allowing for
small trade-offs in a and power.
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APPENDIX I
SAS macro for sample sizes for single-stage phase II designs based on exact binomial test
********************************************************************;
*Macro requires to specify values of P0 and P1        *;
*P0Low is the start value of P0 and P0high is the highest value of *;
*P0.   *;
*The same is true of P1low and P1high. In this example, P0 ranges  *;
*from 0.50 to 0.55 and ranges from 0.6 to 0.65.    *;
*  *;
*All sample sizes and cut of values (r) are provided for varying   *;
*sample sizes from 1 to 600.              *;
*     *;
*The cut off value for alpha = 0.07 and for power = 0.77          *;
 *;
*  *;
*This example provides solutions for P0 between 50% and 55% and  *;
*P1 values between 60% and 65%.  *;
********************************************************************;
%macro bintest(p0low¼,p0high¼,p1low¼,p1high¼);
data bintest1;
do p0¼&p0low to &p0high by 0.01;
do p1 ¼ &p1low to &p1high by 0.01;
do n ¼ 1 to 600 by 1;
do r ¼ 1 to 600 by 1;
output; output; output; output;
end; end; end;end;
run;
%mend;
%bintest(p0low¼0.5, p0high¼0.55,p1low¼0.60,p1high¼0.65);
data bintest2 ;
set bintest1;
r2¼rþ1; **we require 4r responses out of n**
if p1 o¼ p0 then delete;
if r 4¼ n then delete;
y¼probbnml(p0,n,r2);** prob. of or2 responders under the assumption*;
**that standard response P0 is true**;
alpha ¼ 1-y ; ** this is prob. 4r2 responders for P0**;
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z¼probbnml(p1,n,r2);** prob. of or2 responders under the assumption*;
**that experimental response P1 is true**;
power ¼ 1-z ; ** this is prob. 4r2 responders for P1**;
diff ¼ p1-p0;
if power 40.76 and alpha o0.08;
run;
data bintest3 (keep¼p0 p1 r2 n alpha power diff);
set bintest2;
run;
APPENDIX II
R Function in package Clinfun
Example function call: ph2single(P0, P1, alpha, beta and n)
Where,
P0, unacceptable response rate
P1, response rate that is desirable
Alpha, threshold for the probability of declaring drug desirable under P0
Beta, threshold for the probability of rejecting the drug under P1
n: number of designs with given alpha and beta
The ph2single wall gives values of: n, r, alpha and the type I and type II errors.
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